[1]乔喜婷,王 昊△,杨 林,等.复元活血汤合化积丸联合肝动脉栓塞化疗术治疗原发性肝癌临床研究*[J].陕西中医,2019,(8):998-1000.
　QIAO Xiting,WANG Hao,YANG Lin,et al.Fuyuan Huoxue decoction plus Huaji pills and hepatic artery embolization in the treatment of primary liver cancer[J].,2019,(8):998-1000.
点击复制

复元活血汤合化积丸联合肝动脉栓塞化疗术治疗原发性肝癌临床研究*
分享到：

《陕西中医》[ISSN:1000-7369/CN:61-1281/TN]

卷:
期数:
2019年8期
页码:
998-1000
栏目:
临床研究
出版日期:
2019-08-05

文章信息/Info

Title:
Fuyuan Huoxue decoction plus Huaji pills and hepatic artery embolization in the treatment of primary liver cancer
文章编号:
DOI:10.3969/j.issn.1000-7369.2019.08.004
作者:
乔喜婷; 王 昊△; 杨 林; 邱春丽; 李志路
陕西省咸阳市中心医院（咸阳 712000）
Author(s):
QIAO Xiting; WANG Hao; YANG Lin; et al.
Central Hospital of Xianyang in Shaanxi Province (Xianyang 712000 )
关键词:
复元活血汤; 肝动脉栓塞化疗术; 原发性肝癌; 生存情况; 不良反应; 临床疗效
Keywords:
Key words Fuyuan Huoxue decoction; Hepatic artery embolization chemotherapy; Primary liver cancer; Survival; Adverse reactions; Clinical efficacy
分类号:
R735.7
文献标志码:
A
摘要:
摘 要 目的：探讨复元活血汤合化积丸联合肝动脉栓塞化疗术治疗原发性肝癌的临床疗效。方法：按照便利抽样法选取原发性肝癌患者102例作为研究对象，随机分为研究组和对照组各51例，对照组采取肝动脉栓塞化疗术治疗，研究组在对照组的基础上采用复元活血汤合化积丸治疗，治疗时间为6周，进行3年随访。比较两组患者治疗前、治疗后6个月KPS评分、汉密尔顿抑郁量表（HAMD）评分、甲胎蛋白（AFP）水平，以及治疗后3年疾病复发、生存情况、不良反应发生情况。结果：治疗前，研究组的KPS评分、HAMA评分、AFP水平与对照组比较差异均无统计学意义（P＞0.05）。治疗后研究组KPS评分高于对照组，HAMA评分、AFP水平低于对照组，均有统计学意义（P＜0.05）。肿瘤复发率研究组为13.73%，低于对照组的49.02%；研究组1年生存率、2年生存率、3年生存率分别为88.24%、76.47%、58.82%，高于对照组的66.67%、45.10%、29.41%，均有统计学意义（P＜0.05）。不良反应发生率研究组为47.06%，低于对照组的82.35%，均有统计学意义（P＜0.05）。结论：复元活血汤合化积丸联合肝动脉栓塞化疗术治疗原发性肝癌，有助于降低患者的抑郁情况和AFP水平，减少肿瘤复发和不良反应，提高患者的生存率。
Abstract:
Abstract Objective：To explore the clinical efficacy of Fuyuan Huoxue decoction plus Huaji pills combined with transcatheter arterial chemoembolization in the treatment of primary liver cancer. Methods：According to the convenience sampling method,102 patients with primary liver cancer were randomly divided into study group (51 cases) and control group (51 cases). Hepatic artery embolization chemotherapy was used. The study group was treated with Fuyuan Huoxue decoction and Huaji pills on the basis of the control group. The treatment time was 6 weeks and followed up for 3 years.KPS scores,Hamilton depression scale (HAMD) scores,alpha-fetoprotein (AFP) levels,and disease recurrence,survival,and adverse events were compared between the two groups before treatment and 6 months after treatment. Results：Before treatment,the KPS score,HAMA score and AFP level of the study group were not significantly different from the control group,and there was no significant difference (P＞0.05).After treatment,the KPS score of the study group was higher than that of the control group,and the HAMA score and AFP level were lower than the control group (P＜0.05).The tumor recurrence rate was 13.73% in the study group,which was lower than the control group of 49.02%.The 1-year survival rate,2-year survival rate,and 3-year survival rate of the study group were 88.24%,76.47%,and 58.82%,respectively,which were higher than the control group's 66.67%,45.10%,and 29.41%,all of which were statistically significant (P＜0.05).The incidence of adverse reactions was 47.06% in the study group,which was lower than that in the control group (82.35%),which was statistically significant (P＜0.05). Conclusion：Fuyuan Huoxue decoction combined with hepatic artery embolization chemotherapy for primary liver cancer has a positive effect ,and also helps patients to better receive treatment and reduce depression and AFP levels. Reducing tumor recurrence and adverse reactions and improving the survival rate of patients can be promoted clinically.

参考文献/References:

[1] 李 亮,徐 港. 肝动脉栓塞化疗联合中医姑息疗法对中晚期原发性肝癌的临床观察[J]. 四川中医,2017,35(5)：108-111.
[2] 王天平,王 俊. 介入加外放射与单纯介入治疗原发性肝癌临床疗效对比研究[J]. 陕西医学杂志,2016,45(10)：1311-1312.
[3] 李志坚,海 军. 晚期肝癌合并上消化道出血的聚乙烯醇肝动脉栓塞介入治疗价值[J]. 肝脏,2017,22(2)：176-177.
[4] Niska JR,Keane FK,Wolfgang JA,et al. Impact of intravenous contrast enhancement phase on target definition for hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (IHC)：Observations from patients enrolled on a prospective phase 2 trial[J]. Practical Radiation Oncology,2016,6(1)：9-16.
[5] 袁喆娱. 循证护理运用在肝动脉栓塞化疗术治疗肝癌患者护理中的有效性评价[J]. 中国医药指南,2018,16(12)：242-243.
[6] 顾 露,吴冬梅,谢 坪. 中药联合肝动脉化疗栓塞术治疗原发性肝癌系统评价的再评价[J]. 中国药房,2016,27(15):2073-2076.
[7] 胡 玥,王瑞平,张 微. 疏肝健脾解毒汤联合肝动脉化疗栓塞术治疗原发性肝癌的临床研究[J]. 陕西中医,2015,36(9)：1139-1140.
[8] 中华人民共和国卫生部. 原发性肝癌诊疗规范：2011年版[J]. 临床肝胆病杂志,2011,20(11)：929-946.
[9] 王 娟. 中年男性晚期肝癌患者家属的死亡教育现状研究进展[J]. 齐鲁护理杂志,2016,22(17)：52-55.
[10] 周 萍,侯文强,吕元军,等. 肝脏CT灌注成像对肝动脉栓塞化疗联合中药治疗原发性肝癌的临床疗效评价[J]. 解放军医药杂志,2016,28(6)：52-54.
[11] Brown KT,Do RK,Gonen M,et al. Randomized trial of hepatic artery embolization for hepatocellular carcinoma using doxorubicin-eluting microspheres compared with embolization with microspheres alone[J]. Journal of Clinical Oncology Official Journal of the American Society of Clinical Oncology,2016,34(17)：2046-2053.
[12] 陈光耀,肖愫祺,梁汉坚. 复元活血汤合桃红四物汤对髋关节置换术后患者凝血功能及DVT发生的影响[J]. 中医临床研究,2018,10(13)：9-11.
[13] 侯艳林. 艾迪注射液联合CAFI化疗方案对原发性肝癌患者KPS评分及肿瘤疾病控制率的影响[J]. 北方药学,2018,15(7)：56-57.

备注/Memo

备注/Memo:
*陕西省自然科学基金资助项目（2018JQ8014）
更新日期/Last Update: 2019-08-15